Safety and Tolerability Study of XXB750 in Heart Failure Participants With Reduced or Mildly Reduced Ejection Fraction (HFrEF/HFmrEF)
Completed · Phase 1 · Has a placebo group
Conditions studied: Heart Failure With Reduced Ejection Fraction (HFrEF), or Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
In brief
This is a multi-center, randomized, sponsor open-label, participant- and investigator-blinded, placebo-controlled, single and multiple dose study to investigate the safety and tolerability of XXB750 in HFrEF/HFmrEF.
Key facts
- Study ID
- NCT05328752
- Run by
- Novartis Pharmaceuticals
- People needed
- 27
- Starts
- 2022-05-17
- Expected to finish
- 2024-01-18
- Last updated by the study team
- 2025-09-30
Who can join
Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Nature Coast Clinical Research LLC — Inverness, Florida, United States
- Jacksonville Ctr for Clin Rea Main Centre — Jacksonville, Florida, United States
- Fairview Health Services . — Saint Paul, Minnesota, United States
- Novartis Investigative Site — Groningen, Netherlands
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.